Statistical analysis
No calculation of statistical power was performed for this study because no analyses of clinical significance were planned. Safety data (vital signs, ECGs, routine laboratory tests, physical examinations, and AEs) were summarized descriptively. Plasma pemigatinib concentrations and PK parameters (maximum observed plasma concentration [Both the efficacy and the safety population included all patients who received at least 1 dose of study drug. The PK/pharmacodynamic population included all patients who received at least one dose of study drug and provided at least one postdose plasma sample for PK/pharmacodynamic measurement. No comparisons are made between patients or against historical controls; only comparisons to pretreatment conditions were made.